Welcome to our dedicated page for brks news (Ticker: brks), a resource for investors and traders seeking the latest updates and insights on brks stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect brks's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of brks's position in the market.
Brooks Automation (Nasdaq: BRKS) announced plans to separate into two independent, publicly-traded companies. This strategic move aims to enhance focus and operational agility in their distinct markets: a life sciences company with $449 million in revenue and an automation technology firm generating $553 million. The separation, targeting completion by end of 2021, will be executed through a pro-rata distribution of shares to shareholders. No shareholder vote is required, and further details will be provided in future SEC filings.
Brooks Automation (Nasdaq: BRKS) has announced a definitive agreement to acquire Precise Automation, a leader in collaborative robots, for approximately $70 million. The transaction is set to close by the end of April 2021, subject to customary conditions. Precise Automation generated $17 million in revenue over the last year and specializes in automation solutions for various sectors, including laboratory and semiconductor industries. The acquisition aims to enhance Brooks' product offerings and capitalize on growth opportunities in the collaborative robot market.
Brooks Automation (Nasdaq: BRKS) is set to announce its fiscal 2021 second quarter results on May 10, 2021, after market close. The announcement will cover the period ending March 31, 2021. A conference call and live webcast will be held on the same day at 4:30 p.m. ET, with access available via the Brooks website. The company specializes in life science sample-based solutions and semiconductor manufacturing, providing cold-chain sample management, genomic services, and precision robotics for industry leaders globally.
Brooks Automation (Nasdaq: BRKS) will participate in the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, with a 40-minute webcast starting at 12:45 p.m. ET. The webcast can be accessed via the company's investor relations website, and a replay will be available post-event. Brooks provides advanced solutions in life sciences and semiconductor manufacturing, focusing on cold-chain sample management and genomic services. With over 40 years of experience, the company supports top global pharmaceutical, biotech, and semiconductor industries.
Brooks Automation (Nasdaq: BRKS) will participate in the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2021. A live webcast will begin at 1:15 p.m. ET and can be accessed via the Brooks investor relations website. A replay will be available post-event. Brooks is a leader in life science sample management and semiconductor manufacturing solutions. Its offerings include cold-chain sample management and genomic services, essential for pharmaceutical and biotech sectors. The company operates globally from its headquarters in Chelmsford, MA.
Brooks Automation reported first quarter fiscal 2021 results with revenue of $250 million, marking a 19% year-over-year increase. Semiconductor Solutions revenue was $131 million, up 11%, while Life Sciences grew 29% to $118 million. Diluted EPS from continuing operations rose to $0.36, a 103% increase year-over-year. The company anticipates revenue for the second quarter between $267 million and $283 million and expects diluted EPS in the range of $0.33 to $0.42.
Brooks Automation (Nasdaq: BRKS) will announce its fiscal 2021 first-quarter results on February 2, 2021, after market close. The quarter ended on December 31, 2020. A conference call will be hosted at 4:30 p.m. ET on the same day, accessible via phone and live webcast. Brooks specializes in life science sample management and semiconductor manufacturing solutions, providing services globally to top pharmaceutical and semiconductor manufacturing firms. The replay of the earnings call will be available starting February 3, 2021, at 8:30 a.m. ET.
Brooks Automation (Nasdaq:BRKS) announced that its genomics division, GENEWIZ, has secured one of six IDIQ contracts from the National Cancer Institute (NCI). This contract will enable GENEWIZ to provide whole exome sequencing for NCI’s Center for Cancer Genomics over the next three years. The collaboration aims to generate data to advance cancer research and improve patient outcomes. The award reflects GENEWIZ's strong reputation in the cancer research community and its commitment to supporting vital genomic research initiatives.
Brooks Automation (Nasdaq:BRKS) announced its participation in two virtual investor conferences: the 23rd Annual Needham Virtual Growth Conference on January 12, 2021, starting at 10:45 a.m. ET, and the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, beginning at 4:30 p.m. ET.
Webcasts for these events can be accessed via the Investor Relations page on Brooks Automation’s website. Replays will be available post-presentation.
Brooks Automation (Nasdaq: BRKS) announced the unexpected passing of Mr. A. Clinton Allen, a long-serving director since 2003, who died on December 6, 2020, at 76. The Board Chairman, Joe Martin, expressed deep sadness over the loss, highlighting Mr. Allen's leadership and contributions to the company. Allen had extensive experience in investment banking and served on multiple public company boards. Brooks Automation specializes in life science sample management and semiconductor manufacturing solutions, with a significant global presence.
